Le produit a bien été ajouté au panier.

discount label
Ac-KVPRNQDWL-OH
Vue en 3D

Biosynth logo

Ac-KVPRNQDWL-OH

Ref. 3D-PP44976

Taille indéfinieÀ demander
Livraison estimée en/au États-Unis, le mardi 5 novembre 2024

Informations sur le produit

Nom :
Ac-KVPRNQDWL-OH
Synonymes :
  • Ac-Lys-Val-Pro-Arg-Asn-Gln-Asp-Trp-Leu-OH
Description :

Peptide Ac-KVPRNQDWL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Ac-KVPRNQDWL-OH include the following: Bioactive peptide nanodrugs based on supramolecular assembly for boosting immunogenic cell death-induced cancer immunotherapy Y Liu, R Chang, R Xing, X Yan - Small Methods, 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/smtd.202201708 Supramolecular cancer photoimmunotherapy based on precise peptide self-assembly design Y Liu, L Zhang, R Chang, X Yan - Chemical Communications, 2022 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2022/cc/d1cc06355c Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy Y Cai, W Ran, Y Zhai, J Wang, C Zheng, Y Li - Biomaterials , 2020 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2020/bm/c9bm01380f Absolute quantitation of tryptophan-containing peptides and amyloid beta-peptide fragments by coulometric mass spectrometry Y Ai , P Zhao , PIJ Fnu , H Chen - of the American Society for Mass , 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jasms.1c00121 Peptide delivery systems for cancer vaccines X He , SI Abrams, JF Lovell - Advanced Therapeutics, 2018 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adtp.201800060 gp100/pmel 17 is a murine tumor rejection antigen: induction of"self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand WW Overwijk , A Tsung, KR Irvine - The Journal of , 1998 - rupress.orghttps://rupress.org/jem/article-abstract/188/2/277/7712 Antitumor peptide-based vaccine in the limelight T Kumai, H Yamaki, M Kono, R Hayashi, R Wakisaka - Vaccines, 2022 - mdpi.comhttps://www.mdpi.com/2076-393X/10/1/70 Peptide-based vaccines RJ Nevagi , I Toth , M Skwarczynski - Peptide applications in biomedicine , 2018 - Elsevierhttps://www.sciencedirect.com/science/article/pii/B9780081007365000120 Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses NM Molino , M Neek , JA Tucker, EL Nelson, SW Wang - Biomaterials, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0142961216000764 Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100 MJB van Stipdonk, D Badia-Martinez , M Sluijter - Cancer research, 2009 - AACRhttps://aacrjournals.org/cancerres/article-abstract/69/19/7784/550084 The good, the bad and the ugly: how altered peptide ligands modulate immunity M Katsara, G Minigo , M Plebanski - Expert opinion on , 2008 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14712590802494501 Peptide mimotopes alter T cell function in cancer and autoimmunity JE Slansky, M Nakayama - Seminars in immunology, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1044532320300117 Peptide vaccine formulation controls the duration of antigen presentation and magnitude of tumor-specific CD8+ T cell response H Khong , A Volmari, M Sharma , Z Dai - The Journal of , 2018 - journals.aai.orghttps://journals.aai.org/jimmunol/article/200/10/3464/106644 A Self-Delivery Chimeric Peptide for Photodynamic Therapy Amplified Immunotherapy H Cheng, GL Fan, JH Fan, RR Zheng - Macromolecular , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/mabi.201800410 Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans D van Dinther , M Lopez Venegas, H Veninga, K Olesek - Cancers, 2019 - mdpi.comhttps://www.mdpi.com/2072-6694/11/2/183 Peptide vaccines in melanoma: chemical approaches towards improved immunotherapeutic efficacy B Biri-Kovacs , Z Banoczi , A Tummalapally, I Szabo - Pharmaceutics, 2023 - mdpi.comhttps://www.mdpi.com/1999-4923/15/2/452 An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia AR Shin, SE Lee, H Choi, HJ Sohn, HI Cho - British Journal of , 2020 - nature.comhttps://www.nature.com/articles/s41416-020-0955-y Nanoparticles to improve the efficacy of peptide-based cancer vaccines AL Tornesello , M Tagliamonte , ML Tornesello - Cancers, 2020 - mdpi.comhttps://www.mdpi.com/2072-6694/12/4/1049

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP44976 Ac-KVPRNQDWL-OH

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".